Biohaven Pharmaceutical Holding Stock Performance

BHVN Stock  USD 11.48  0.12  1.06%   
On a scale of 0 to 100, Biohaven Pharmaceutical holds a performance score of 6. The firm shows a Beta (market volatility) of -0.23, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Biohaven Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Biohaven Pharmaceutical is likely to outperform the market. Please check Biohaven Pharmaceutical's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Biohaven Pharmaceutical's price patterns will revert.

Risk-Adjusted Performance

Mild

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Biohaven Pharmaceutical Holding are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Biohaven Pharmaceutical displayed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
1.06
Five Day Return
(1.88)
Year To Date Return
5.9
Ten Year Return
57.26
All Time Return
57.26
1
Biohaven Issues Quarterly Earnings Results
12/03/2025
2
Whats Going On With Biohaven Stock Friday
12/26/2025
3
Acquisition by Antonijevic Irina of 11000 shares of Biohaven Pharmaceutical subject to Rule 16b-3
12/29/2025
4
Biohaven Is Down 6.1 percent After Ending BHV-7000 Depression Trial To Refocus On Epilepsy And Obesity
01/05/2026
5
Biohaven Shares Up 11.9 percent Heres Why
01/07/2026
6
Biohaven Ltd. Shares Surge 3.42 percent to 12.10 Amid Positive Clinical Data - Intellectia AI
01/14/2026
7
Biohaven Shares Gap Up Should You Buy
01/21/2026
8
Acquisition by Kimberly Gentile of 3750 shares of Biohaven Pharmaceutical subject to Rule 16b-3
01/28/2026
9
Here Are Fridays Top Wall Street Analyst Research Calls Amazon.com, Caterpillar, Estee Lauder, JPMorgan, Norfolk Southern, Roku, Snap, Vistra, and More
02/06/2026
10
Biohaven Stock Price Up 8.4 percent - Should You Buy - MarketBeat
02/09/2026
11
Biohaven Trading Up 8.4 percent Following Analyst Upgrade
02/12/2026
Begin Period Cash Flow252.1 M
Total Cashflows From Investing Activities-245 M

Biohaven Pharmaceutical Relative Risk vs. Return Landscape

If you would invest  963.00  in Biohaven Pharmaceutical Holding on November 20, 2025 and sell it today you would earn a total of  185.00  from holding Biohaven Pharmaceutical Holding or generate 19.21% return on investment over 90 days. Biohaven Pharmaceutical Holding is currently generating 0.4281% in daily expected returns and assumes 5.2623% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Biohaven, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Biohaven Pharmaceutical is expected to generate 6.95 times more return on investment than the market. However, the company is 6.95 times more volatile than its market benchmark. It trades about 0.08 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.18 per unit of risk.

Biohaven Pharmaceutical Target Price Odds to finish over Current Price

The tendency of Biohaven Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 11.48 90 days 11.48 
about 32.84
Based on a normal probability distribution, the odds of Biohaven Pharmaceutical to move above the current price in 90 days from now is about 32.84 (This Biohaven Pharmaceutical Holding probability density function shows the probability of Biohaven Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Biohaven Pharmaceutical Holding has a beta of -0.23 suggesting as returns on the benchmark increase, returns on holding Biohaven Pharmaceutical are expected to decrease at a much lower rate. During a bear market, however, Biohaven Pharmaceutical Holding is likely to outperform the market. Additionally Biohaven Pharmaceutical Holding has an alpha of 0.5866, implying that it can generate a 0.59 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Biohaven Pharmaceutical Price Density   
       Price  

Predictive Modules for Biohaven Pharmaceutical

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biohaven Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biohaven Pharmaceutical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
6.6311.8116.99
Details
Intrinsic
Valuation
LowRealHigh
8.2013.3818.56
Details
16 Analysts
Consensus
LowTargetHigh
19.0520.9423.24
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-1.7-0.87-0.34
Details

Biohaven Pharmaceutical Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Biohaven Pharmaceutical is not an exception. The market had few large corrections towards the Biohaven Pharmaceutical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biohaven Pharmaceutical Holding, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biohaven Pharmaceutical within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.59
β
Beta against Dow Jones-0.23
σ
Overall volatility
1.35
Ir
Information ratio 0.1

Biohaven Pharmaceutical Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biohaven Pharmaceutical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biohaven Pharmaceutical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Biohaven Pharmaceutical had very high historical volatility over the last 90 days
Biohaven Pharmaceutical Holding currently holds 36.58 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity.
Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0.
Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (582.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48.
Biohaven Pharmaceutical has a poor financial position based on the latest SEC disclosures
Roughly 74.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies
Latest headline from thelincolnianonline.com: Biohaven Trading Up 8.4 percent Following Analyst Upgrade

Biohaven Pharmaceutical Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Biohaven Stock often depends not only on the future outlook of the current and potential Biohaven Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biohaven Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding91.2 M
Cash And Short Term Investments486 M

Biohaven Pharmaceutical Fundamentals Growth

Biohaven Stock prices reflect investors' perceptions of the future prospects and financial health of Biohaven Pharmaceutical, and Biohaven Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biohaven Stock performance.

About Biohaven Pharmaceutical Performance

By examining Biohaven Pharmaceutical's fundamental ratios, stakeholders can obtain critical insights into Biohaven Pharmaceutical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Biohaven Pharmaceutical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.28)(1.34)
Return On Capital Employed(1.73)(1.81)
Return On Assets(1.24)(1.30)
Return On Equity(2.30)(2.18)

Things to note about Biohaven Pharmaceutical performance evaluation

Checking the ongoing alerts about Biohaven Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biohaven Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biohaven Pharmaceutical had very high historical volatility over the last 90 days
Biohaven Pharmaceutical Holding currently holds 36.58 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity.
Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0.
Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (582.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48.
Biohaven Pharmaceutical has a poor financial position based on the latest SEC disclosures
Roughly 74.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies
Latest headline from thelincolnianonline.com: Biohaven Trading Up 8.4 percent Following Analyst Upgrade
Evaluating Biohaven Pharmaceutical's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biohaven Pharmaceutical's stock performance include:
  • Analyzing Biohaven Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biohaven Pharmaceutical's stock is overvalued or undervalued compared to its peers.
  • Examining Biohaven Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Biohaven Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biohaven Pharmaceutical's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Biohaven Pharmaceutical's stock. These opinions can provide insight into Biohaven Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biohaven Pharmaceutical's stock performance is not an exact science, and many factors can impact Biohaven Pharmaceutical's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Will Biotechnology sector continue expanding? Could Biohaven diversify its offerings? Factors like these will boost the valuation of Biohaven Pharmaceutical. Projected growth potential of Biohaven fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biohaven Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(7.52)
Return On Assets
(1.06)
Return On Equity
(5.22)
Understanding Biohaven Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biohaven's accounting equity. The concept of intrinsic value - what Biohaven Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biohaven Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biohaven Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biohaven Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biohaven Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.